Research analysts at Royal Bank Of Canada began coverage on shares of BIOVERATIV INC (NASDAQ:BIVV) in a report issued on Thursday. The firm set a “sector perform” rating and a $59.00 price target on the biotechnology company’s stock. Royal Bank Of Canada’s price objective would suggest a potential upside of 6.92% from the company’s current price.
Several other analysts have also issued reports on the stock. William Blair started coverage on shares of BIOVERATIV INC in a research report on Wednesday, June 28th. They set a “market perform” rating for the company. Cowen and Company upgraded shares of BIOVERATIV INC from a “market perform” rating to an “outperform” rating in a research report on Monday, July 10th. Jefferies Group LLC restated a “buy” rating on shares of BIOVERATIV INC in a research report on Friday, June 30th. Zacks Investment Research upgraded shares of BIOVERATIV INC from a “hold” rating to a “strong-buy” rating and set a $73.00 target price for the company in a research report on Tuesday, July 25th. Finally, Credit Suisse Group upgraded shares of BIOVERATIV INC from an “underperform” rating to a “neutral” rating and boosted their target price for the company from $47.00 to $52.00 in a research report on Wednesday, May 24th. One investment analyst has rated the stock with a sell rating, ten have issued a hold rating, five have given a buy rating and one has given a strong buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $60.33.
Shares of BIOVERATIV INC (BIVV) opened at 55.18 on Thursday. The stock has a market capitalization of $5.97 billion and a PE ratio of 13.12. BIOVERATIV INC has a 52 week low of $41.88 and a 52 week high of $57.82. The company’s 50 day moving average is $56.37 and its 200-day moving average is $54.74.
BIOVERATIV INC (NASDAQ:BIVV) last announced its earnings results on Wednesday, August 2nd. The biotechnology company reported $0.88 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.71 by $0.17. The business had revenue of $289.10 million for the quarter, compared to the consensus estimate of $269.00 million. The business’s quarterly revenue was up 37.5% compared to the same quarter last year. During the same quarter last year, the firm posted $0.59 earnings per share. On average, equities analysts predict that BIOVERATIV INC will post $2.89 earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: “BIOVERATIV INC (BIVV) Coverage Initiated at Royal Bank Of Canada” was posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this article on another site, it was copied illegally and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://www.chaffeybreeze.com/2017/09/16/bioverativ-inc-bivv-coverage-initiated-at-royal-bank-of-canada.html.
In other BIOVERATIV INC news, insider Diantha Duvall sold 818 shares of BIOVERATIV INC stock in a transaction that occurred on Wednesday, June 28th. The shares were sold at an average price of $60.47, for a total transaction of $49,464.46. Following the transaction, the insider now owns 2,128 shares of the company’s stock, valued at $128,680.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Brian S. Posner purchased 1,000 shares of the stock in a transaction on Wednesday, August 9th. The shares were purchased at an average cost of $59.19 per share, for a total transaction of $59,190.00. Following the acquisition, the director now directly owns 6,693 shares of the company’s stock, valued at $396,158.67. The disclosure for this purchase can be found here.
About BIOVERATIV INC
Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.
Receive News & Ratings for BIOVERATIV INC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOVERATIV INC and related companies with MarketBeat.com's FREE daily email newsletter.